Cyclophosphamide in the therapy of multiple sclerosis: A longitudinal study on intrathecal immunoglobulin response

E. Millefiorini, M. D. Giovanni, S. Bernardi, M. G. Grasso, M. Salvetti, F. Nuccetelli, D. Gambi

Research output: Contribution to journalArticlepeer-review

Abstract

Eleven patients with chronic-progressive Multiple Sclerosis were treated with 700 gr/m2 of cyclophosphamide (CTX) intravenously for five days and a single dose was repeated every two months for 12 months. All patients were submitted to a lumbar puncture before therapy, one month and six months after the beginning of the treatment in order to analyze the behaviour of liquoral IgG in our therapeutic schedule with CTX. The liquoral IgG resulted elevated in all patients at the basal sampling. In the second lumbar puncture the IgG were significantly decreased while a trend towards increased levels was again observed after six months from the treatment.

Original languageEnglish
Pages (from-to)59-62
Number of pages4
JournalInternational Journal of Immunopathology and Pharmacology
Volume3
Issue number1
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Cyclophosphamide in the therapy of multiple sclerosis: A longitudinal study on intrathecal immunoglobulin response'. Together they form a unique fingerprint.

Cite this